BG62759B1 - Средство и метод за лечение на автоимунни заболявания - Google Patents
Средство и метод за лечение на автоимунни заболявания Download PDFInfo
- Publication number
- BG62759B1 BG62759B1 BG100921A BG10092196A BG62759B1 BG 62759 B1 BG62759 B1 BG 62759B1 BG 100921 A BG100921 A BG 100921A BG 10092196 A BG10092196 A BG 10092196A BG 62759 B1 BG62759 B1 BG 62759B1
- Authority
- BG
- Bulgaria
- Prior art keywords
- tbg
- autoimmune diseases
- treatment
- glycoprotein
- trophoblastic
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 title claims abstract description 15
- 102000007502 Pregnancy-Specific beta 1-Glycoproteins Human genes 0.000 claims abstract description 38
- 108010085648 Pregnancy-Specific beta 1-Glycoproteins Proteins 0.000 claims abstract description 38
- 230000000403 immunocorrecting effect Effects 0.000 claims abstract description 7
- 210000005259 peripheral blood Anatomy 0.000 claims description 11
- 239000011886 peripheral blood Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 230000007812 deficiency Effects 0.000 claims description 3
- 230000001573 trophoblastic effect Effects 0.000 claims 2
- 210000005087 mononuclear cell Anatomy 0.000 abstract description 16
- 238000012360 testing method Methods 0.000 abstract description 15
- 210000004027 cell Anatomy 0.000 abstract description 4
- 230000035945 sensitivity Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 6
- 201000006417 multiple sclerosis Diseases 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000005713 exacerbation Effects 0.000 description 3
- 230000005714 functional activity Effects 0.000 description 3
- 230000003169 placental effect Effects 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000005021 gait Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 206010003084 Areflexia Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010027925 Monoparesis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000001977 ataxic effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 201000005737 orchitis Diseases 0.000 description 1
- 208000008016 pathologic nystagmus Diseases 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011867 re-evaluation Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU9494008169A RU2056852C1 (ru) | 1994-03-18 | 1994-03-18 | Средство для лечения аутоиммунных заболеваний с иммунодефицитом супрессоров и способ лечения аутоиммунных заболеваний |
| PCT/RU1995/000047 WO1995025531A1 (fr) | 1994-03-18 | 1995-03-16 | Agent therapeutique contre les maladies auto-immunes et mode de traitement |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BG100921A BG100921A (en) | 1997-12-30 |
| BG62759B1 true BG62759B1 (bg) | 2000-07-31 |
Family
ID=20153349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG100921A BG62759B1 (bg) | 1994-03-18 | 1996-10-18 | Средство и метод за лечение на автоимунни заболявания |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6150326A (el) |
| EP (1) | EP0790059B1 (el) |
| JP (1) | JPH09510473A (el) |
| KR (1) | KR100382252B1 (el) |
| CN (1) | CN1146156A (el) |
| AT (1) | ATE260111T1 (el) |
| AU (1) | AU699896B2 (el) |
| BG (1) | BG62759B1 (el) |
| CA (1) | CA2185892A1 (el) |
| CZ (1) | CZ285856B6 (el) |
| DE (2) | DE790059T1 (el) |
| ES (1) | ES2107980T1 (el) |
| FI (1) | FI963671A (el) |
| GE (1) | GEP20012377B (el) |
| GR (1) | GR980300023T1 (el) |
| HU (1) | HUT75720A (el) |
| NO (1) | NO963911L (el) |
| PL (1) | PL179765B1 (el) |
| RU (1) | RU2056852C1 (el) |
| SK (1) | SK281948B6 (el) |
| UA (1) | UA26939C2 (el) |
| WO (1) | WO1995025531A1 (el) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0030729D0 (en) * | 2000-12-16 | 2001-01-31 | Univ Nottingham | Substituted-4-Quinolones |
| CA2501940A1 (en) * | 2002-10-09 | 2004-04-22 | Tolerrx, Inc. | Molecules preferentially associated with effector t cells or regulatory t cells and methods of their use |
| RU2303995C1 (ru) * | 2006-04-28 | 2007-08-10 | Халлар Абдумуслимович Алиханов | Средство, обладающее иммунорегуляторным свойством и его применение для лечения аутоиммунных заболеваний |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2862449D1 (en) * | 1977-08-22 | 1984-11-22 | Nat Res Dev | Macromolecular covalent conjugates, methods for preparing and pharmaceutical compositions containing them |
| JPS61186322A (ja) * | 1985-02-13 | 1986-08-20 | Nippon Univ | 免疾調節剤 |
| IT1188646B (it) * | 1986-04-09 | 1988-01-20 | Ellem Ind Farmaceutica | Tripeptide ad attivita' immunostimolante |
| US4803072A (en) * | 1986-09-10 | 1989-02-07 | Smithkline Beckman Corporation | Immunomodulation |
| FR2609632B1 (fr) * | 1987-01-21 | 1991-03-29 | Shelly Marc | Nouvelle application therapeutique de la 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinon-6-one et les compositions pharmaceutiques destinees a cet usage |
| US5169835A (en) * | 1989-01-18 | 1992-12-08 | Oklahoma Medical Research Foundation | Pregancy specific proteins applications |
| FR2650183A1 (fr) * | 1989-07-25 | 1991-02-01 | Pasteur Institut | Proteines immunostimulantes, anticorps monoclonaux et polyclonaux correspondants, hybridomes correspondants et application de ces produits a des fins therapeutiques et de diagnostic |
| US5118669A (en) * | 1989-09-20 | 1992-06-02 | Hitachi Chemical Co., Ltd. | Peptides and intermediates therefor useful as antiallergic agents, vasodilators and immunoregulators |
| US5559097A (en) * | 1990-01-12 | 1996-09-24 | Idaho Research Foundation, Inc. | Use of a pregnancy specific protein as an immunosuppressive |
| RU1836957C (ru) * | 1990-03-25 | 1993-08-30 | 2-й Московский государственный медицинский институт им.Н.И.Пирогова | Способ получени трофобластического бета @ -гликопротеина |
| GB2251186A (en) * | 1990-12-04 | 1992-07-01 | Randall Neal Gatz | Polypeptide for use in treatment of autoimmune disease |
-
1994
- 1994-03-18 RU RU9494008169A patent/RU2056852C1/ru not_active IP Right Cessation
-
1995
- 1995-03-16 SK SK1187-96A patent/SK281948B6/sk unknown
- 1995-03-16 CN CN95192635A patent/CN1146156A/zh active Pending
- 1995-03-16 DE DE0790059T patent/DE790059T1/de active Pending
- 1995-03-16 DE DE69532611T patent/DE69532611D1/de not_active Expired - Lifetime
- 1995-03-16 HU HU9602558A patent/HUT75720A/hu unknown
- 1995-03-16 CA CA002185892A patent/CA2185892A1/en not_active Abandoned
- 1995-03-16 AT AT95913445T patent/ATE260111T1/de not_active IP Right Cessation
- 1995-03-16 AU AU20874/95A patent/AU699896B2/en not_active Ceased
- 1995-03-16 ES ES95913445T patent/ES2107980T1/es active Pending
- 1995-03-16 KR KR1019960705237A patent/KR100382252B1/ko not_active IP Right Cessation
- 1995-03-16 WO PCT/RU1995/000047 patent/WO1995025531A1/ru active IP Right Grant
- 1995-03-16 PL PL95316311A patent/PL179765B1/pl unknown
- 1995-03-16 US US08/716,139 patent/US6150326A/en not_active Expired - Fee Related
- 1995-03-16 CZ CZ962747A patent/CZ285856B6/cs not_active IP Right Cessation
- 1995-03-16 JP JP7524566A patent/JPH09510473A/ja not_active Ceased
- 1995-03-16 UA UA96093436A patent/UA26939C2/uk unknown
- 1995-03-16 GE GEAP19953411A patent/GEP20012377B/en unknown
- 1995-03-16 EP EP95913445A patent/EP0790059B1/en not_active Expired - Lifetime
-
1996
- 1996-09-17 FI FI963671A patent/FI963671A/fi not_active IP Right Cessation
- 1996-09-18 NO NO963911A patent/NO963911L/no not_active Application Discontinuation
- 1996-10-18 BG BG100921A patent/BG62759B1/bg unknown
-
1998
- 1998-04-30 GR GR980300023T patent/GR980300023T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SK118796A3 (en) | 1997-06-04 |
| DE69532611D1 (de) | 2004-04-01 |
| AU2087495A (en) | 1995-10-09 |
| CA2185892A1 (en) | 1995-09-28 |
| DE790059T1 (de) | 1998-03-12 |
| EP0790059B1 (en) | 2004-02-25 |
| CZ274796A3 (en) | 1997-06-11 |
| UA26939C2 (uk) | 1999-12-29 |
| RU2056852C1 (ru) | 1996-03-27 |
| PL179765B1 (pl) | 2000-10-31 |
| ATE260111T1 (de) | 2004-03-15 |
| FI963671A (fi) | 1996-11-14 |
| HU9602558D0 (en) | 1996-11-28 |
| PL316311A1 (en) | 1997-01-06 |
| NO963911L (no) | 1996-11-08 |
| BG100921A (en) | 1997-12-30 |
| AU699896B2 (en) | 1998-12-17 |
| EP0790059A1 (en) | 1997-08-20 |
| CN1146156A (zh) | 1997-03-26 |
| ES2107980T1 (es) | 1997-12-16 |
| JPH09510473A (ja) | 1997-10-21 |
| CZ285856B6 (cs) | 1999-11-17 |
| SK281948B6 (sk) | 2001-09-11 |
| GR980300023T1 (en) | 1998-04-30 |
| FI963671A0 (fi) | 1996-09-17 |
| EP0790059A4 (en) | 2000-11-02 |
| KR970701557A (ko) | 1997-04-12 |
| US6150326A (en) | 2000-11-21 |
| WO1995025531A1 (fr) | 1995-09-28 |
| GEP20012377B (en) | 2001-03-25 |
| NO963911D0 (no) | 1996-09-18 |
| KR100382252B1 (ko) | 2003-07-07 |
| HUT75720A (en) | 1997-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA et al. | Studies on the mechanism of the Shwartzman-phenomenon; evidence for the participation of polymorphonuclear leucocytes in the phenomenon. | |
| Klein et al. | Thymoma and polymyositis: onset of myasthenia gravis after thymectomy: report of two cases | |
| Hazleman et al. | Lymphocyte proliferation to artery antigen as a positive diagnostic test in polymyalgia rheumatica. | |
| Barranco | Mixed bullous disease | |
| Brettler et al. | Factor VIII: C concentrate purified from plasma using monoclonal antibodies: human studies | |
| Eisen et al. | Peripheral nerve function in long‐term therapy with diphenylhydantoin: A clinical and electrophysiologic correlation | |
| Caspary et al. | Lymphocyte sensitization to nervous tissues and muscle in patients with the Guillain-Barré syndrome | |
| Oh | 19 Treatment and Management ofDisorders of the Neuromuscular Junction | |
| Painter et al. | Neonatal seizures: diagnosis and treatment | |
| BG62759B1 (bg) | Средство и метод за лечение на автоимунни заболявания | |
| SHUMAN | Relapsing panniculitis (Weber-Christian disease): review of literature and report of a case including treatment with cortisone | |
| Svensson | Role of intravenously infused insulin in treatment of acute pancreatitis: a double-blind study | |
| US2386725A (en) | Therapeutic substance for measles | |
| Giaquinto et al. | Reflex activity of extensor and flexor muscles following muscular afferent excitation during sleep and wakefulness | |
| Sakuta et al. | Diagnostic significance of membrane attack complex and vitronectin in childhood dermatomyositis | |
| Glode et al. | Effect of intravenous immune globulin on the coagulopathy of Kawasaki syndrome | |
| Oh | Treatment and management of | |
| Jansen et al. | Effect of thymectomy on myasthenia gravis and autoimmune thrombocytopenic purpura in a 13-year-old girl | |
| Scherokman et al. | Angiofollicular lymph node hyperplasia and peripheral neuropathy: Case report and literature review | |
| Smolin et al. | High doses of subconjunctival corticosteroid and antibody-forming cells in the eye and draining lymph nodes | |
| SU1640653A1 (ru) | Способ диагностики рассе нного склероза | |
| Tosca et al. | Neuroendocrinological aspects of depression and symptomatological picture | |
| Martins et al. | Type IV hyperlipidemia in cord blood. | |
| Freedman | Anterior uveitis in Bantu children. | |
| Açoğlu et al. | Familial hypokalemic periodic paralysis with mutation in a voltage-gated calcium channel. |